Rosuvastatin and Tamoxifen Interaction
Rosuvastatin and Tamoxifen have a potentially harmful interaction with 75% confidence. Both Rosuvastatin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.
Compound Profiles
Rosuvastatin
HMG-CoA Reductase Inhibitor | Statin for Lipid Management
Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface.
View full profileTamoxifen
Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment
Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Rosuvastatin with Tamoxifen?
Combining Rosuvastatin with Tamoxifen is not recommended. Both Rosuvastatin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is Rosuvastatin and Tamoxifen safe together?
This combination carries significant risk. Both Rosuvastatin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between Rosuvastatin and Tamoxifen?
Both Rosuvastatin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.
How should I time Rosuvastatin and Tamoxifen?
Rosuvastatin has a half-life of ~19 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.